Quince Therapeutics to Execute 1-for-20 Reverse Stock Split on June 29
QNCX sits 21% above its 52-week low of $0.79.
Summary
Quince Therapeutics will implement a 1-for-20 reverse stock split on June 29, 2026, its second such action in under three months, underscoring continued struggles with its stock price and Nasdaq compliance.
Key Events · Corporate Governance and Compliance · QNCX
-
Board Approves 1-for-20 Reverse Split
The board of directors approved a 1-for-20 reverse stock split, following shareholder approval for a range of ratios on June 11, 2026.
-
Effective Date and Trading
The reverse split will be effective at 11:59 pm ET on June 29, 2026, with split-adjusted trading commencing on Nasdaq on June 30, 2026.
-
Second Reverse Split in Three Months
This is the company's second reverse stock split since April 10, 2026, indicating ongoing challenges with maintaining its share price above Nasdaq's minimum bid requirement.
-
Share Count Adjustment
Outstanding shares will decrease from 19,559,257 to approximately 977,963 post-split, with proportional adjustments to options and warrants.
Analysis · QNCX · Life Sciences
This 8-K finalizes the terms of a 1-for-20 reverse stock split, effective June 29, 2026. This marks the second reverse split for the company in less than three months, following a 1-for-10 split in April. The repeated need for reverse splits highlights persistent challenges in maintaining Nasdaq listing requirements and signals ongoing investor concern about the company's long-term viability.
How filings like this one have moved
In the 30 days to Oct 4, 2026, 41.7% of the 300 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -0.48%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, QNCX was trading at $0.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $15.9M. The 52-week trading range was $0.79 to $45.50. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.